THE ECONOMIC BURDEN OF ADJUVANT CHEMOTHERAPY IN GERMANY

Author(s)

Eiermann W1, Rezai M2, Kuemmel S3, Kühn T4, Benkow A5, Hogberg D6, Schweikert B7, Blohmer JU51Rotkreuzklinikum München gGmbH, München, Germany, 2Luisenkrankenhaus, Düsseldorf, Germany, 3Kliniken Essen-Mitte, Essen, Germany, 4Klinikum Esslingen, Esslingen,

OBJECTIVES: In Germany, breast cancer is the most frequent cancer. In 2007, 7.2% of total German health care expenditure was spent on breast cancer. Despite, its important epidemiological and economic burden, literature on cost of chemotherapy in breast cancer is rather scarce in Germany. The objective of this study was to estimate the cost of adjuvant chemotherapy in early stage breast cancer in Germany, using two different perspectives: the sick funds and the society. METHODS: A semi-systematic search of the literature was conducted to identify relevant articles describing the cost of adjuvant chemotherapy in Germany. The electronic database Pubmed and a selection of congress databases were searched using combinations of search terms designed to identify publications describing cost of adjuvant chemotherapy in early stage breast cancer patients. Searches were limited to those published in the English and German language between January 2000 and April 2011. A retrospective multicentre study was conducted to collect chemotherapy-related resources used. Unit costs were collected from public sources (EBM catalogue, Rote list, DRG list). Cost items collected included: chemotherapy drugs, monitoring and administration, prevention and management of adverse events, transportation to the treatment centre, and when using the societal perspective, also sick leaves. RESULTS: A total of 51 patients were included the study. The following adjuvant chemotherapy regimens were given to the patients:  TAC (22%), FEC (20%), FEC+DOC (20%), TC (20%), EC+DOC/PAC (12%) and others (8%). The average total costs for an adjuvant chemotherapy treatment were estimated to be €11,036 in a sick fund perspective and €16,199 in a broader societal perspective. The direct costs were €5722 for chemotherapy drugs, €982 for chemotherapy administration and monitoring, €4228 for supportive drugs and management of adverse events. The indirect costs of sick leaves were €5163. CONCLUSIONS: Adjuvant chemotherapy represents a significant economic burden to the health care system and the society.

Conference/Value in Health Info

2011-11, ISPOR Europe 2011, Madrid, Spain

Value in Health, Vol. 14, No. 7 (November 2011)

Code

PCN55

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×